Псориаз и псориатический артрит в детском возрасте

Псориаз — это хроническое воспалительное заболевание кожи, которое может развиться в любом возрасте человека. Примерно 20–30% пациентов сообщают о возникновении первых высыпаний в период до 18 лет жизни. Одним из коморбидных состояний псориаза является псориатический артрит. Его признаки могут варьировать от легких до крайне деструктивных форм. Боль в суставах, скованность и отек являются наиболее распространенными симптомами. Раннее начало лечения псориатического артрита позволяет контролировать повреждение суставов, которое обычно происходит в течение первых 2 лет заболевания. Среднетяжелое и тяжелое течение псориаза и псориатического артрита может потребовать системной терапии, однако данных об эффективности и токсичности системных агентов в детской популяции не много. В статье представлен обзор исследований эффективности и безопасности этанерцепта при псориатическом артрите в детском возрасте.

1. Sukhatme SV, Gottlieb AB. Pediatric psoriasis: updates in biologic therapies. Dermatol Ther. 2009;22(1):34–39. doi: 10.1111/j.1529-8019.2008.01214.x.

2. Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–987. doi: 10.1016/j.jaad.2009.07.029.

3. Augustin M, Glaeske G, Radtke M, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3): 633–636. doi: 10.1111/j.1365-2133.2009.09593.x.

4. Круглова Л.С., Тамразова О.Б., Иванов Р.А. Псориаз в детском возрасте: клиническое течение и тактика ведения // Журнал Международной Медицины. Педиатрия/Неонатология. — 2019. — Т. 2. — № 36. — С. 19–25.

5. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677–687. doi: 10.1038/jid.2010.340.

6. Olivieri I, D’Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10(9): 531–442. doi: 10.1038/nrrheum.2014.106.

7. Mayo Clinic. Psoriatic Arthritis — Symptoms and Causes. 2016. Available online: https://www.mayoclinic.org/diseases-conditions/psoriatic-arthritis/symptoms-causes/syc-20354076. Accessed on December 12, 2017.

8. Lindqvist URC, Alenius G-M, Husmark T. et al. The Swedish early psoriatic arthritis register — 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol. 2008;35(4):668–673.

9. Gladman DD. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–17. doi: 10.1136/ard.2004.032482.

10. Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol. 2009;5(11):634–641. doi: 10.1038/nrrheum.2009.210.

11. Nigrovic P. Juvenile psoriatic arthritis: bathwater or baby? J Rheumatol. 2009;36(9):1861–1863. doi: 10.3899/jrheum.090510.

12. Stoll M, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437–443. doi: 10.1097/BOR.0b013e328348b278.

13. Flato B, Lien G, Smerdel-Ramoya A, Vinje O. Juvenile psoriatic arthritis: long term outcome and differentiation from other subtypes of juvenile idiopathic arthritis. J Rheumatol. 2009;36(3):642–650. doi: 10.3899/jrheum.080543.

14. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55–78. doi: 10.1016/0049-0172(73)90035-8.

15. Eder L, Gladman DD. Psoriatic arthritis: phenotypic variance and nosology. Curr Rheumatol Rep. 2013;15(3):316. doi: 10.1007/s11926-013-0316-4.

16. Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol. 2011;25(12):1409–1414. doi: 10.1111/j.1468-3083.2011.03985.x.

17. Ogdie A, Weiss P. The Epidemiology Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568. doi: 10.1016/j.rdc.2015.07.001.

18. McGonagle D, Helliwell P, Veale D. Enthesitis in psoriatic disease. Dermatology. 2012;225(2):100–109. doi: 10.1159/000341536.

19. Sakkas L, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013;43(3):325–334. doi: 10.1016/j.semarthrit.2013.04.005.

20. Weiss PF, Chauvin NA, Klink AJ, et al. Detection of enthesitis in children with enthesitis-related arthritis: dolorimetry compared to ultrasonography. Arthritis Rheumatol. 2014;66(1):218–227. doi: 10.1002/art.38197.

21. Coates L, Hodgson R, Conaghan P, Freeston J. MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012;26(6):805–822. doi: 10.1016/j.berh.2012.09.004.

22. Gladman D, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40(8):1357–1359. doi: 10.3899/jrheum.130163.

23. Healy P, Groves C, Chandramohan M, Helliwell P. MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices. Rheumatology (Oxford). 2008; 47(1):92–95. doi: 10.1093/rheumatology/kem315.

24. Tuttle KS, Vargas SO, Callahan MJ, et al. Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity. Pediatr Rheumatol Online J. 2015;13:7. doi: 10.1186/s12969-015-0003-2.

25. Love T, Gudjonsson J, Valdimarsson H, Gudbjornsson B. Psoriatic arthritis and onycholysis — results from the cross-sectional Reykjavik psoriatic arthritis study. J Rheumatol. 2012;39(7): 1441–1444. doi: 10.3899/jrheum.111298.

26. Love T, Gudbjornsson B, Gudjonsson J, Valdimarsson H. Psoria tic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. J Rheumatol. 2007;34(10):2082–2088.

27. Aydin S, Castillo-Gallego C, Ash Z, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225(3):231–235. doi: 10.1159/000343607.

28. Круглова Л.С., Хотко А.А., Петрий М.А. Раннее назначение генно-инженерной биологической терапии пациентам с псо риазом // Медицинский Алфавит. Дерматология. — 2019. — Т. 1. — № 7(382). — С. 25–28.

29. Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis — a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46(2):253–256. doi: 10.1093/rheumatology/kel214.

30. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27. doi: 10.1016/j.jaad.2005.07.073.

31. Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171:1123–1128. doi: 10.1111/bjd.13272.

32. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasala zine and placebo in the treatment of psoriatic arthritis: a Depart ment Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39(12):2013–2020. doi: 10.1002/art.1780391210.

33. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70(2):272–277. doi: 10.1136/ard.2010.129379.

34. Helliwell P, FitzGerald O, Pedersen R, et al. Comparison of composite disease activity scores in psoriatic arthritis. In: 3th World Psoriasis & Psoriatic Arthritis Conference 2012 “Psoriasis — a global health challenge”, June 27 — July 1, 2012, Stockholm, Sweden. Abstr. pp. 4–5; P009.

35. Di Lernia V, Guarneri C, Stingeni L, et al. Effectiveness of etanercept in children with plaque psoriasis in real practice: a oneyear multicenter retrospective study. J Dermatolog Treat. 2018; 29(3):217– 219. doi: 10.1080/09546634.2017.1364692.

36. Dogra S, Mahajan R. Biologics in pediatric psoriasis — efficacy and safety. Expert Opin Drug Saf. 2018;17(1):9–16. doi: 10.1080/14740338.2018.1391787.

37. Ramiro S, Smolen JS, Landewe R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2016;75(3):490–498. doi: 10.1136/annrheumdis-2015-208466.

38. Coates LC, Kavanaugh A, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA. J Rheumatol. 2014;41(11):2273–2276. doi: 10.3899/jrheum.140875.

39. Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(Suppl 1): i37–i46. doi: 10.1093/rheumatology/kez383.

40. Coates LC, Moverley AR, McParland L, et al. Effect of tight control inflammation in early psoriatic arthritis (TICOPA): a UK multicenter, open-label, randomized controlled trial. Lancet. 2015;386(10012): 2489–2498. doi: 10.1016/S0140-6736(15)00347-5.

41. Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12(12):743–750. doi: 10.1038/nrrheum.2016.183.

42. Оказание медицинской помощи детям с псориазом / под ред. А.А. Баранова, Л.С. Намазовой -Барановой , Н.Н. Мурашкинаю — М.: ПедиатрЪ; 2016. — 64 с.

43. Намазова-Баранова Л.С., Мурашкин Н.Н., Амбарчян Э.Т., Мате рикин А.И. Системная терапия псориаза в детском возрасте (часть II): вопросы биологической терапии // Вестник дерматологии и венерологии. — 2017. — № 6. — С. 100–107. doi: 10.25208/0042-4609-2017-93-6-100-107.

44. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a Randomized, Controlled Phase 3 Trial. Arthritis Rheumatol. 2019;71(7):1112–1124. doi: 10.1002/art.40851.

45. Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280–287.e1–3. doi: 10.1016/j.jaad.2015.09.056.

46. Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64–70. doi: 10.1016/j.jaad.2010.02.060.

47. Paller A, Pariser D, Siegfried E, Kricorian G. Safety and efficacy of etanercept treatment in children and adolescents with plaque psoriasis: 96-week results of open-label extension study. Conference: 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309. J Am Acad Dermatol. 2010;62(3 Suppl 1):AB11.

48. Мурашкин Н.Н., Амбарчян Э.Т. Сравнительная оценка эффективности и безопасности ингибиторов TNF и IL12/23 в терапии псориаза у детей // Педиатрическая фармакология. — 2018. — Т. 15. — № 6. — С. 455–463. doi: 10.15690/pf.v15i6.1983.

49. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol. 2003;49(2 Supple):105–111. doi: 10.1016/mjd.2003.554.

50. Siegfried EC, Eichenfield LF, Paller AS, et al. Intermittent Etanercept Therapy in Pediatric Patients With Psoriasis. J Am Acad Dermatol. 2010;63(5):769–774. doi: 10.1016/j.jaad.2009.10.046.

51. Foeldvari I, Constantin T, Vojinovic J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitisrelated arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Paediatric Rheumatology International Trials Organisation (PRINTO). Arthritis Res Ther. 2019;21(1):125. doi: 10.1186/s13075-019-1916-9.